Newshot Article title: 2026 Commercial Insurance Innovative Drug Catalog Expands to 28 Drugs, World's First Solid Tumor CAR-T and China's First Hemophilia Gene Therapy Drug Selected
Body:
- Day/Night Follow System Light Dark
2026 Commercial Insurance Innovative Drug Catalog Expands to 28 Drugs, World's First Solid Tumor CAR-T and China's First Hemophilia Gene Therapy Drug Selected
IT Home, November 14 news, according to a report by CCTV News today, the National Healthcare Security Administration disclosed the latest adjustment results of the commercial health insurance innovative drug catalog at the 2026 Innovative Drug High-Quality Development Conference. After this round of adjustment, the commercial insurance innovative drug catalog added 12 drugs, bringing the total number of drugs in the catalog to 28.
The newly added products are concentrated in the field of high-value innovative therapies. Among them, surajacabtagene autoleucel injection (trade name: Kailimei), the world's first approved CAR-T product for solid tumors, entered the catalog. The drug targets CLDN18.2 and is indicated for advanced gastric/gastroesophageal junction adenocarcinoma that has failed at least second-line treatment, with a single manufacturing price of 990,000 yuan.
CAR-T (chimeric antigen receptor T-cell immunotherapy, which modifies a patient's own T cells to recognize and attack tumor cells) had previously been approved only for hematologic malignancies, and surajacabtagene autoleucel extends the application of this therapy to solid tumors.
Also included was porpodacogene injection (trade name: Xinjiuning), China's first gene therapy drug for hemophilia. The drug uses an AAV vector to deliver the coagulation factor IX gene and is intended for moderate to severe hemophilia B. The patient out-of-pocket price has dropped from the initial 2.79 million yuan to 1.39 million yuan or less, and it has obtained about 30% reimbursement coverage under Huiminbao in many places.
The catalog size increased from 19 to 28 rather than simply 19 plus 12 equals 31 because of the two-way flow of the linkage mechanism. In May 2026, the National Healthcare Security Administration established for the first time in the annual adjustment plan a formal linkage channel between the commercial insurance innovative drug catalog and the basic medical insurance catalog, allowing drugs in the commercial insurance catalog to apply for inclusion in the basic medical insurance catalog.
章轲, Director of the National Healthcare Security Administration, said that during the year, 2 drugs from the 2025 commercial insurance catalog had been successfully transferred to the basic medical insurance catalog and continue to apply the relevant exclusion support policies. This means that some products originally in the commercial insurance catalog, after proving clinical value and fund affordability, have gained a path to migrate to the "basic protection" level.
IT Home note: The first edition of the commercial insurance innovative drug catalog was released in December 2025 and included 19 drugs at that time, mainly CAR-T, rare disease drugs, and Alzheimer's disease treatments. The 2026 adjustment, while expanding the absolute number, further strengthened the catalog's positioning as a transitional payment channel for innovative drugs that are "beyond the basic protection positioning but highly innovative and with significant patient benefits."
Related Articles
- 114 new drugs enter the 2025 National Medical Insurance Drug Catalog, 19 drugs included in the first edition of the commercial insurance innovative drug catalog
Sites under Ruanmei: IT Home Zuihuimai - Rebate and Cashback Coupons iPhone Home Win7 Home Win10 Home Win11 Home
Software under Ruanmei: Ruanmei Mobile APP Applications Rubik's Cube Zuihuimai Yaozhi